A call to action on Overdose Awareness Day
By Guest Contributor | August 31, 2018
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Ask About Adherence: New study finds one-third of newly diagnosed diabetic patients aren’t starting treatment
By Guest Contributor | August 29, 2018
Ask About Adherence is a blog series featuring Q&A’s with experts and new medication adherence resources. In this post, we are pleased to share a blog post from Lauren Gilstrap, MD, MPH. ...
Read More
Number of value-based contracts continues to rise
By Michelle Drozd | August 27, 2018
The list of publicly announced value-based contracts (VBCs) – also called results-based contracts – between biopharmaceutical companies and health plans continued to grow over the last quarter –...
Read More
Fact Check Friday: Getting the facts straight about negotiation in Medicare Part B
By Nicole Longo | August 24, 2018
Medicare Part B has been a hot topic in Washington, DC, this summer with an increasing number of conversations about how the program works. Unfortunately, a common misconception keeps popping up...
Read More
69 percent of patients abandon medicines when cost sharing is more than $250
By Holly Campbell | August 23, 2018
New research from the IQVIA Institute for Human Data Science shows that when cost sharing rises, patients are more likely to abandon their medicines. In 2017, 69 percent of commercially insured...
Read More
Ask About Adherence: Taking adherence research to a global level
By Guest Contributor | August 22, 2018
Ask About Adherence is a blog series featuring Q&A’s with experts and new medication adherence resources. In this post, we are pleased to share a blog post from Leah Zullig, PhD, MPH and Sabina De...
Read More
New analysis finds 340B medicine sales hit record high in 2017 and continue to grow as a share of total drug spending
By Nicole Longo | August 20, 2018
How big is the 340B program, and what share of the prescription medicine market does it represent? Those are popular questions of late as stakeholders discuss ways to improve the 340B program. In...
Read More
New analysis in Health Affairs reinforces one-third of medicine list price rebated back to supply chain
By Holly Campbell | August 13, 2018
An analysis published in a Health Affairs blog post by Nancy L. Yu, Preston Atteberry and Peter B. Bach of the Memorial Sloan Kettering Cancer Center reinforces that one-third of medicine list...
Read More
PhRMA member companies R&D investments hit record high in 2017 - $71.4 billion
By Tim McClung | August 9, 2018
PhRMA member companies invested $71.4 billion in research and development (R&D) in 2017, the highest level of investment on record, according to the 2018 PhRMA member annual survey, released in...
Read More
Medicare Monday (100)
340B Spotlight (37)
Cost & Consequence (0)
